Chen Chen, Wang Mengyao, Tu Daoyuan, Cao Jun, Zhang Chi, Bai Dousheng
Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Department of Anesthesiology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Med Oncol. 2025 Jan 30;42(3):58. doi: 10.1007/s12032-025-02612-9.
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a highly aggressive malignancy with limited viable therapeutic options. For early HCC, resection surgery is currently the most effective treatment. However, in advanced stages, resection alone does not sufficiently address the disease, so finding a method with a better prognosis is necessary. Anoikis, known as matrix detachment-induced apoptosis or detachment-induced cell death, is crucial for tissue development and homeostasis. Cancer cells develop means to evade anoikis, e.g. anoikis resistance, thereby allowing for cells to survive under anchorage-independent conditions. HCC cells often acquire resistance to anoikis, allowing them to survive after detaching from the extracellular matrix and contributing to tumor spread. This review discusses the mechanisms of anoikis in HCC, exploring the potential of drug-induced anoikis and targeting anoikis resistance as promising therapeutic strategies for treating HCC, analyzing the value of anoikis in the immune of HCC, and propose potential pathways in oncotherapy, which can provide background knowledge for subsequent related research.
肝细胞癌(HCC)是最常见的原发性肝癌,是一种侵袭性很强的恶性肿瘤,可行的治疗选择有限。对于早期HCC,手术切除目前是最有效的治疗方法。然而,在晚期,单纯手术切除并不能充分解决该疾病,因此有必要找到一种预后更好的方法。失巢凋亡,即基质脱离诱导的凋亡或脱离诱导的细胞死亡,对组织发育和体内平衡至关重要。癌细胞会发展出逃避失巢凋亡的方法,例如失巢凋亡抗性,从而使细胞能够在非锚定依赖条件下存活。HCC细胞通常会获得对失巢凋亡的抗性,使其在从细胞外基质脱离后仍能存活,并促进肿瘤扩散。本综述讨论了HCC中失巢凋亡的机制,探讨了药物诱导失巢凋亡的潜力以及靶向失巢凋亡抗性作为治疗HCC的有前景的治疗策略,分析了失巢凋亡在HCC免疫中的价值,并提出了肿瘤治疗中的潜在途径,可为后续相关研究提供背景知识。